Dry powders inhalers in constrained clinical situations;Les poudres sèches dans les situations cliniques extrêmes

Revue des Maladies Respiratoires

Volumn 22, Issue 4, 2005, Pages 605-613

  Roche, N ^a   Dessanges, J F ^b   Dubus, J C ^c  

^a HÔTEL DIEU   (France)

^b Institut Cochin   (France)

^c TIMONE HOSPITAL   (France)

Author keywords

Asthma; COPD; Dry powder inhalers; Inhalation Therapy; Obstructive lung diseases

Indexed keywords

ASMABEC; ASMASAL; BEMEDREX; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; BUVENTAL; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL FUMARATE; HISTAMINE; METHACHOLINE; MIFLASONE; MIFLONIL; NOVOPULMON; SALBUTAMOL; SALMETEROL XINAFOATE; TERBUTALINE;

ACUTE DISEASE; ADULT; AEROSOL; AIRFLOW; AIRWAY OBSTRUCTION; ASTHMA; BRONCHOSPASM; CHILD; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE ASSOCIATION; DRY POWDER; HUMAN; IN VITRO STUDY; PATIENT EDUCATION; PATIENT SELECTION; POWDER INHALER; PRACTICE GUIDELINE; REVIEW;

EID: 25844481058     PISSN: 07618425     EISSN: None     Source Type: Journal    
DOI: 10.1019/200530058     Document Type: Review

References (32)

1. Liard R, Zureik M, Aubier M, Korobaefif M, Henry C, Neukirch F: Mauvaise utilisation des aérosols-doseurs pressurisés par des asthmatiques traités en médecine de ville en France. Rev Epidemiol Sante Publique 1995; 43: 242-9.
2. Dubus JC, Stremler N, Mely L, Bruguerolle B: Influence de la chambre d'inhalation sur la bronchodilatation chez l'enfant asthmatique. Rev Mal Respir 1997; 14: 193-8.
3. Hickey AJ, Marionen TB: Behavior of hygroscopic pharmaceutical aerosols and the influence of hydrophobic additives. Pharm Res 1993; 10: 1-7.
4. Engel T, Heinig JH, Madsen F, Nikander K: Peak inspiratory flow and inspiratory vital capacity of patients with asthma measured with and without a new dry-powder inhaler device (Turbuhaler). Eur Respir J 1990; 3: 1037-41.
5. Brown PH, Ning ACWS, Greening AP, McLean A, Crompton GK: Peak inspiratory flow through Turbuhaler® in acute asthma. Eur Respir J 1995; 8: 1940-1.
6. Kamps AWA, Brand PLP, Roorda RJ: Variation of peak inspiratory flow through dry powder inhalers in children with stable and unstable asthma. Pediatr Pulmonol 2004; 37: 65-70.
7. Everard ML, Devadason SG, Le Souef PN: Flow early in the inspiratory manoeuvre affects the aerosol particle size distribution from a Turbuhaler. Respir Med 1997; 91: 624-8.
8. Svartengren K, Lindestad PA, Svartengren M, Philipson K, Bylin G, Camner P: Added external resistance reduces oropharyngeal deposition and increases lung deposition of aerosol particles in asthmatics. Am J Respir Crit Care Med 1995; 152: 32-7.
9. Kim CS, Kang TC: Comparative measurement of lung deposition of inhaled fine particles in normal subjects and patients with obstructive airway disease. Am J Respir Crit Care Med 1997; 155: 899-905.
10. Assi KH, Chrystyn H: The different resistance of dry powder inhalers. Am J Respir Crit Care Med 2001; 163: A443.
11. Vogelberg C, Kremer HJ, Ellers-Lenz B, Enger M, Maus J, Conrad F, Hermann R: Clinical evaluation of the peak inspiratory flow generated by asthmatic children through the Novolizer. Respiratory Medicine 2004; 98: 924-31.
12. Newhouse MT, Nantel NP, Chambers CB, Pratt B, Parry-Billings M: Clickhaler (a novel dry powder inhaler) provides similar bronchodilation to pressurized metered-dose inhaler, even at low flow rates. Chest 1999; 115: 952-6.
13. Koskela T, Malmström K, Sairanen U, Peltola S, Keski-Karhu J, Silvasti M: Efficacy of salbutamol via Easyhaler® unaffected by low inspiratory flow. Respir Med 2000; 94: 1229-33.
14. Pedersen S, Hansen OR, Fuglsang G: Influence of inspiratory flow rate upon the effect of a Turbuhaler. Arch Dis Child 1990; 65: 308-10.
15. Ståhl E, Ribeiro LB, Sandahl G: Dose response to inhaled terbutaline powder and peak inspiratory flow through Turbuhaler® in children with mild to moderate asthma. Pediatr Pulmonol 1996; 22: 106-10.
16. Ortiz G, Menendez R: The effects of inhaled albuterol and salmeterol in 2- to 5-year-old asthmatic children as measured by impulse oscillometry. J Asthma 2002; 39: 531-6.
17. Beach JR, Bromly CL, Avery AJ, Reid RWEC, Walters EH, Hendrick DJ: Speeds of action of single doses of formoterol and salbutamol compared with placebo in reversing methacholine-induced bronchoconstriction. Pulm Pharmacol 1996; 9: 245-9.
18. Politick MJ, Boorsma M, Aalbers R: Comparison of formoterol, salbutamol and salmeterol in methacholine-induced severe bronchoconstriction. Eur Respir J 1999; 13: 988-92.
19. Zetterström O, Lähelmä S, Keski-Karhu J, Silvasti M, Östling-Kulling E, Ahonen A: Salbutamol via Easyhaler® is at least as effective as salbutamol via Turbuhaler® in the treatment of histamine-induced bronchoconstriction. Respir Med 2000; 94: 1097-102.
20. Tønnesen F, Laursen LC, Evald T, Ståhl E, Ibsen TB: Bronchodilating effect of terbutaline powder in acute severe bronchial obstruction. Chest 1994; 105: 697-700.
21. 2-agonists administered by a dry powder inhaler can be used in acute asthma. Respir Med 1998; 92: 167-72.
22. Drblik S, Lapierre G, Thivierge R, Turgeon J, Gaudreault P, Cummins-McManus B, Verdy I, Haddon J, Lee J, Spier S: Comparative efficacy of terbutaline sulphate delivered by Turbuhaler dry powder inhaler or pressurised metered dose inhaler with Nebuhaler spacer in children during an acute asthmatic episode. Arch Dis Child 2003; 88: 319-23.
23. Cazzola M, D'Amato M, Califano C, Di Perna F, Calderaro F, Matera MG, D'Amato G: Formoterol as dry powder oral inhalation compared with salbutamol metered-dose inhaler in acute exacerbations of chronic obstructive pulmonary disease. Clin Ther 2002; 24: 595-604.
24. 2-agonists in the treatment of acute exacerbations of COPD. Clin Drug Invest 2002; 22: 369-76.
25. Hansen NCG, Evald T, Ibsen TB: Terbutaline inhalations by the Turbuhaler® as replacement for domiciliary nebulizer therapy in severe chronic obstructive pulmonary disease. Respir Med 1994; 88: 267-71.
26. Hansen NCG, Andersen PB: Salbutamol powder inhaled from the Diskhaler compared to salbutamol as nebulizer solution in severe chronic airways obstruction. Respir Med 1995; 89: 175-9.
27. Mahler DA, Wire P, Horstman D, Chang CN, Yates J, Fischer T, Shah T: Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002; 166: 1084-91.
28. Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A, Anderson J, Maden C: Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003; 361: 449-56.
29. Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H: Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003; 22: 912-9.
30. Szafranski W, Cukier A, Ramirez A, Menga G, Sansores R, Nahabedian S, Peterson S, Olsson H: Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003; 21: 74-81.
31. Molimard M, Raherison C, Lignot S, Depont F, Abouelfath A, Moore N: Assessment of handling of inhaler devices in real life: an observational study in 3 811 patients in primary care. J Aerosol Med 2003; 16: 249-54.
32. National Institutes of Health: National Heart, Lung and Blood Institute: Global Initiative for Asthma. Global strategy for asthma management and prevention. NHLBI/WHO Worshop report. Bethesda, MD: National Institutes of Health (publication n° 02-3659) updated 2003.